ft 23 mar 94 survey pharmaceut 9 select approach case studi schere plough research institut us pharmaceut compani impend healthcar reform promis era increas cost contain price control weight restrict measur innov drug industri adapt surviv accord dr robert spiegel senior vice presid clinic research schere plough research institut market new drug never subsid believ alway market profit market drug compani develop novel product satisfi unmet need import therapeut area say 1993 schere plough spent usdollar 578m research develop invest expect increas dollar 600m year despit continu commit r amp fund schere plough admit cost driven market trigger chang approach new world forc us even adapt research develop process say dr spiegel schere plough adapt evolutionari three year ago compani set pharmaceut econom unit design assess econom cost qualiti life benefit potenti new drug earliest possibl stage evalu exactli schere plough expect bring market product fulli develop promin part core r amp process say dr spiegel combin select approach r amp knowledg way discov breakthrough product drug compani inevit expos greater risk mean manufactur increasingli dare decid compound back dr spiegel say go alzheim drug winner pharmaceut industri nice pot gold end process lot loser along way willing conduct research high risk area guarante commerci success raul cesan presid schere laboratori suggest want develop someth uniqu yet may end someth margin improv develop compound may offer slightli better safeti profil product alreadi market luxuri research base drug compani longer afford certain case margin improv give system exactli politician govern offici want lower price two three four product price collaps immedi argu raul cesan research schere plough cover six main therapeut area anti infec tive oncolog allergi dermatolog cardiovascular central nervou system accord dr spiegel secret compani r amp success lie balanc discoveri area support research quit comfort scientif field high risk area great potenti yield explain time brand new area regulatori environ clinic develop environ also unknown area high potenti success worth take risk howev incent take risk could soon disappear price control propos healthcar reform approv propos sever review ultim price drug even breakthrough product give disincent much risk money would put type activ warn dr spiegel case believ current market forc take care price control within drug industri 1993 annual report publish last week schere plough announc 1991 1993 held averag us net prescript drug price increas rate increas consum price index cpi 1994 expect price rise increas cpi price moder dramat comment raul cesan individu compani may suffer loss appetit r amp risk take us drug industri whole maintain commit r amp teamwork joint ventur allianc univers research depart smaller biotechnolog compani establish pharmaceut compani show pool resourc drug compani continu search innov product futur dr spiegel predict incent form allianc research area spread bet certainli concept embrac annual report schere plough say 25 per cent research dollar target biotechnolog anoth form allianc seen us drug compani tap market manag care last year merck amp co acquir health mainten organis medco contain servic dollar 6bn move wide regard attempt protect market share effect acquisit chang merck mission research base pharmaceut compani major player healthcar market redefinit compani busi strategi anticip schere plough ensur long term surviv beyond healthcar reform compani believ continu invest r amp pipelin essenti raul cesan conclud find success drug eventu otherwis cannot surviv